Antineoplastic- Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors

Antineoplastic cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of targeted oncology agents that block the activity of cyclin-dependent kinases 4 and 6 Clinically, these agents—such as palbociclib, ribociclib, and abemaciclib—are primarily indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, typically administered in combination with endocrine therapy

Antineoplastic cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of targeted oncology agents that block the activity of cyclin-dependent kinases 4 and 6 Clinically, these agents—such as palbociclib, ribociclib, and abemaciclib—are primarily indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, typically administered in combination with endocrine therapy

By inhibiting these enzymes, the drugs prevent the phosphorylation of retinoblastoma protein, halting cell cycle progression from the G1 phase to the S phase and arresting the proliferation of tumor cells

Clinically, these agents—such as palbociclib, ribociclib, and abemaciclib—are primarily indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, typically administered in combination with endocrine therapy